Ibuprofeno Kabi (Ibuprofen)

Ibuprofen inhibits the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin production, ibuprofen reduces the sensitization of pain receptors, lowers the hypothalamic set‑point for temperature, and dampens the inflammatory response, providing analgesic, antipyretic, and anti‑inflammatory effects.

The appropriate dose of Ibuprofeno Kabi is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and renal function. Healthcare professionals calculate the infusion rate and total daily amount according to established hospital protocols and the product’s labeling.

Safety of ibuprofen during pregnancy and lactation depends on the trimester and clinical context. Generally, ibuprofen is avoided in the third trimester because of potential fetal cardiovascular effects. During the first and second trimesters, the prescriber must weigh benefits against risks. Ibuprofen does pass into breast milk in small amounts, so a risk‑benefit assessment is required before use while breastfeeding.

To order Ibuprofeno Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Ibuprofeno Kabi offers the same pharmacologic profile as other ibuprofen products but in an intravenous form, allowing rapid onset and use when oral intake is impossible. Compared with stronger injectable NSAIDs such as ketorolac, ibuprofen generally has a lower risk of gastrointestinal ulceration and renal toxicity, though dosing limits and monitoring requirements remain similar.

Ibuprofeno Kabi must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, the vial should be inspected for particulate matter and used within the time frame indicated on the label after removal from refrigeration.

Ibuprofeno Kabi is administered by intravenous infusion. The prescribing clinician determines the infusion rate and total dose, which is typically diluted in an appropriate carrier solution and infused over a specified period, often 15‑30 minutes, according to hospital protocols and the patient’s clinical status.

Serious risks include gastrointestinal bleeding, acute renal impairment, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke, especially in patients with existing cardiovascular disease. Prompt recognition of symptoms such as severe abdominal pain, sudden drop in urine output, rash, or chest discomfort is essential.

Ibuprofeno Kabi should be avoided in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe uncontrolled hypertension, advanced heart failure, and in the third trimester of pregnancy. Caution is also advised for patients with impaired renal or hepatic function, and those taking anticoagulants or other NSAIDs.